Jushi Holdings Secures $160M Term Loan to Refinance Debt, Extends Maturity to 2029
JUSHF has more than doubled off its 52-week low of $0.233.
Summary
Jushi Holdings Inc. secured a new $160 million term loan to refinance existing debt, bolstering liquidity and extending maturities despite reporting an increased net loss for FY2025.
Key Events · Financing and Capital Events · JUSHF
-
Debt Refinancing Completed
On March 27, 2026, the company refinanced $132.3 million of existing debt (2024 Term Loan and Second Lien Notes) with a new $160 million senior secured term loan. The new loan bears a 12.5% interest rate and matures in March 2029. The CEO, James Cacioppo, and a significant equity holder, Denis Arsenault, participated in the new loan with principal amounts of $27.99 million and $21.02 million, respectively.
-
FY2025 Financial Performance
Jushi Holdings reported a net loss of $68.6 million for the fiscal year ended December 31, 2025, an increase from a $48.8 million net loss in FY2024. Gross profit declined by 4% to $114.0 million, with the gross profit margin decreasing from 46% to 43%. However, Adjusted EBITDA increased by 9% to $50.3 million.
-
Improved Liquidity Outlook
Following the debt refinancing, management believes that existing cash and cash from operations will be sufficient to meet working capital and capital expenditure needs for at least the next twelve months. The new 2026 Term Loan includes a financial covenant requiring the company to maintain a minimum unrestricted cash balance of $15 million.
-
Significant Tax Uncertainty
The company disclosed a $177.2 million liability for unrecognized tax benefits as of December 31, 2025, related to its position on IRC Section 280E. This position, which excludes certain business expenses from limitations, may be challenged by the IRS, posing a substantial contingent liability.
Analysis · JUSHF · Life Sciences
Jushi Holdings Inc. successfully refinanced $132.3 million in maturing debt with a new $160 million senior secured term loan, extending its maturity to March 2029. This critical financing event significantly strengthens the company's liquidity and provides essential operating runway, especially given its current market capitalization. The participation of the CEO and a significant equity holder in the new loan demonstrates insider confidence. While the company reported an increased net loss for fiscal year 2025 and faces a substantial unrecognized tax liability related to IRC Section 280E, the debt refinancing addresses immediate solvency concerns. Additionally, the passage of adult-use cannabis legislation in Virginia, pending gubernatorial action, presents a significant future revenue growth opportunity.
At the time of this filing, JUSHF was trading at $0.51 on OTC in the Life Sciences sector, with a market capitalization of approximately $99.4M. The 52-week trading range was $0.23 to $0.98. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.